Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19577718 | 1.00 | ATF4 (0.54) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL22990649 | 1.00 | ATF4 (0.54) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL19577632 | 1.00 | ATF4 (0.54) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL23624503 | 0.96 | ATF4 (0.51) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL23624531 | 0.95 | ATF4 (0.50) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL23624603 | 0.95 | ATF4 (0.50) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL23624613 | 0.95 | ATF4 (0.50) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL19568597 | 0.84 | ATF4 (0.56) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL22627624 | 0.84 | ATF4 (0.56) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 | |
| SCHEMBL22627657 | 0.84 | ATF4 (0.56) | ATF4SMN1; SMN2ALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778575-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2021-02-17 | — | — | EP | disclosed |